Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio --(BUSINESS WIRE)--Apr.
MASON, Ohio --(BUSINESS WIRE)--Apr. 10, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ®
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter
MASON, Ohio --(BUSINESS WIRE)--Mar. 12, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-Mini ™ devices in the United States , and EnCompass ®
MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2025-- AtriCure, Inc. (Nasdaq: ATRC) , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the
MASON, Ohio --(BUSINESS WIRE)--Dec. 23, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
MASON, Ohio --(BUSINESS WIRE)--Nov. 20, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
MASON, Ohio --(BUSINESS WIRE)--Nov. 7, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage management devices in the U.S. International revenue of $20.5 million – an increase of 23.3% year over
MASON, Ohio --(BUSINESS WIRE)--Oct. 28, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
MASON, Ohio --(BUSINESS WIRE)--Oct. 15, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third
MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated
